PT - JOURNAL ARTICLE AU - Qibin Liu AU - Xuemin Fang AU - Shinichi Tokuno AU - Ungil Chung AU - Xianxiang Chen AU - Xiyong Dai AU - Xiaoyu Liu AU - Feng Xu AU - Bing Wang AU - Peng Peng TI - Prediction of the clinical outcome of COVID-19 patients using T lymphocyte subsets with 340 cases from Wuhan, China: a retrospective cohort study and a web visualization tool AID - 10.1101/2020.04.06.20056127 DP - 2020 Jan 01 TA - medRxiv PG - 2020.04.06.20056127 4099 - http://medrxiv.org/content/early/2020/04/16/2020.04.06.20056127.short 4100 - http://medrxiv.org/content/early/2020/04/16/2020.04.06.20056127.full AB - Background Wuhan, China was the epicenter of the 2019 coronavirus outbreak. As a designated hospital, Wuhan Pulmonary Hospital has received over 700 COVID-19 patients. With the COVID-19 becoming a pandemic all over the world, we aim to share our epidemiological and clinical findings with the global community.Methods In this retrospective cohort study, we studied 340 confirmed COVID-19 patients from Wuhan Pulmonary Hospital, including 310 discharged cases and 30 death cases. We analyzed their demographic, epidemiological, clinical and laboratory data and implemented our findings into an interactive, free access web application.Findings Baseline T lymphocyte Subsets differed significantly between the discharged cases and the death cases in two-sample t-tests: Total T cells (p < 2·2e-16), Helper T cells (p < 2·2e-16), Suppressor T cells (p = 1·8-14), and TH/TS (Helper/Suppressor ratio, p = 0·0066). Multivariate logistic regression model with death or discharge as the outcome resulted in the following significant predictors: age (OR 1·05, p 0·04), underlying disease status (OR 3·42, p 0·02), Helper T cells on the log scale (OR 0·22, p 0·00), and TH/TS on the log scale (OR 4·80, p 0·00). The McFadden pseudo R-squared for the logistic regression model is 0·35, suggesting the model has a fair predictive power.Interpretation While age and underlying diseases are known risk factors for poor prognosis, patients with a less damaged immune system at the time of hospitalization had higher chance of recovery. Close monitoring of the T lymphocyte subsets might provide valuable information of the patient’s condition change during the treatment process. Our web visualization application can be used as a supplementary tool for the evaluation.Funding The authors report no funding.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors report no funding.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used to support the findings of this study are available from the corresponding author upon request.